Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06963567

Left Ventricular Thrombus Registry

Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber.

Having a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis.

A sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Left Ventricular Thrombus

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with LV thrombus or;
  • Patients at risk for developing LV thrombus (e.g severe LV dysfunction, LV aneurysm, MI.

Exclusion criteria

  • Age < 18 years
  • Unable to consent

Treatment and study plan

Primary outcomes

  1. Composite Result

    Time frame: From baseline to final 12 month follow up (+/- 2 months)

    To measure the composite result of major bleeding (BARC >3), stroke and systemic embolisation, and all-cause mortality

Secondary outcomes

  1. CMR prediction of thrombus

    Time frame: From baseline to 6 month follow up (+/- 3 months)

    To assess CMR based risk prediction model of recurrence of LV thrombus

  2. Blood Test

    Time frame: From baseline to 6 month follow up (+/- 3 months)

    To assess blood test variables in the persistence or recurrence of LV thrombus

  3. Quality of Life Questionnaire

    Time frame: From baseline to final 12 month follow up (+/- 2 months)

    Participants quality of life (QoL) will be measured using European Quality of Life-5 Dimensions - 5 levels (EQ-5D-5L) questionnaire at baseline and 12 months

Sponsors and collaborators

Lead sponsor

Queen Mary University of London

Other

Registry information

Official study title

Observational Registry to Determine the Predictors and Outcomes of Patients at Risk of and Diagnosed With Left Ventricular Thrombus

Acronym: LVT Registry

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
May 9, 2025
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.